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The impact of renal impairment on the pharmaco-
kinetics of many drugs is widely appreciated; 
chronic kidney disease (CKD) and end-stage 
renal disease (ESRD) can alter drug disposition 
by reducing the systemic clearance of renally 
cleared drugs and affecting protein and tissue 
binding [1,2]. Over the past decade, there has been 
evidence demonstrating that renal failure not 
only alters elimination in the kidney, but also the 
nonrenal disposition of drugs that are extensively 
metabolized by the liver [3–6]. It is assumed that 
dysfunction in the kidney results in pathological 
changes in other organs, including the liver. It is 
likely that renal failure influences hepatic drug 
metabolism, either by inducing or suppressing 
hepatic enzymes, or by its effects on other variables 
such as absorption, protein binding, tissue distri-
bution, hepatic blood flow and accumulation of 
metabolites. Depending on the interplay between 
these parameters and the characteristics of an 
administered drug, varying degrees of impaired 
systemic clearance and first-pass metabolism are 
anticipated. Other factors that may be respon-
sible for the reduced nonrenal clearance of drugs 
in renal failure include alterations in transporter 
systems or transporter activity [6–8].
Patients included in Phase III clinical studies 
are usually restricted to a well-defined population, 
and subpopulations, such as patients with CKD 
or hepatic impairment, are often excluded or are 
under-represented. Consequently, data relating 
to the risk of increased or decreased exposure in 
subpopulations are limited. Regulatory guidances 
on conducting studies in patients with CKD are 
available from both the US FDA [201] and the 
EMA [202] with recommendations concerning 
study design, data ana lysis and labeling. Overall, 
the two guidances are very similar, recommending 
that a study be performed in patients with renal 
impairment if decreased renal function is likely to 
affect the pharmacokinetics of a drug or its metab-
olites. In the FDA’s 1998 guidance document, the 
main emphasis was on investigating drugs that 
are mainly excreted renally [203]. The results of a 
recent survey of 94 approved new drug applica-
tions (NDAs) for small-molecule entities indicated 
that only 57% of these NDAs included study data 
in CKD subjects [9]. Of the new drugs that were 
predominantly eliminated by nonrenal processes, 
such as hepatic metabolism and or/transporters, 
41% had pharmacokinetic data that were signifi-
cantly altered in subjects with CKD, to such an 
extent that dose adjustment was recommended. 
Therefore, the FDA has proposed a decision tree 
in which drugs eliminated predominantly by non-
renal routes may be investigated initially using a 
reduced pharmacokinetic study in subjects with 
ESRD [201]. If the results demonstrate a clinically 
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significant difference in pharmacokinetics, then a full study would 
be required. An interesting drug development perspective on the 
implications of the decision tree has been presented [10].
The primary goal of the studies in patients with impaired renal 
function is to determine if the pharmacokinetics of the drug are 
altered to such an extent that dosage should be adjusted from that 
established in the Phase III clinical trial. Even after assessing the 
effects of renal impairment on the pharmaco kinetics of a drug, 
data relating to the risk of increased or decreased exposure in sub-
populations may be so limited that extensive covariate ana lysis 
cannot be performed. Although identification and quantification 
of covariates, particularly population pharmacokinetic models, is 
now viewed as an integral part of drug development, determining 
covariates using this approach is not always straightforward and 
complications caused by bias and competition between multiple 
variables are well known and have been described in the litera-
ture [11]. At best, it is likely that an average recommended dose can 
be derived for patients that are categorized according to the extent 
of their renal insufficiency. 
Modeling and simulation of the processes that define the plasma 
concentration–time course of a drug – namely, absorption, distribu-
tion, metabolism and elimination (ADME) – using a mechanistic 
approach may help to predict the potential exposure of individual 
patients with CKD to a given dose [12,13]. Development of in vitro–
in vivo extrapolation (IVIVE) approaches to predict pharmacoki-
netic parameters has accelerated mainly due to the increasing avail-
ability of extensive in vitro systems that act as surrogates for in vivo 
reactions relevant to ADME and advances in the understanding of 
the required population variables (demographic, anatomical, genetic 
and physio logical parameters). The purpose of this article is to dis-
cuss the application of the IVIVE approach to predict the impact 
of CKD on pharmacokinetic parameters. The effects of CKD and 
ESRD on drug disposition have been discussed extensively in other 
reviews [1,2]. Although an overview of these will be presented, the 
focus of this article is to discuss how the CKD-induced changes 
can be incorporated into a physiologically based pharmaco kinetic 
(PBPK) model to simulate and predict drug disposition and its 
associated variability in patients with renal impairment. 
CKD: definitions & scope of the problem 
Chronic kidney disease is a progressive loss of renal function over 
a period of months or years. Markers of renal function include 
renal plasma and blood flow, glomerular filtration rate (GFR) and 
tubular function. Among these three parameters of renal function, 
estimation of GFR and creatinine clearance (CL
CR
) is the most 
commonly applied approach to assess renal function. Recent pro-
fessional guidelines use GFR to classify the severity of CKD in five 
stages, with stage 1 being the mildest and usually causing few symp-
toms, and stage 5 being a severe illness with poor life expectancy if 
untreated. The US Kidney Disease Outcomes Quality Initiatives 
of the National Kidney Foundation defines stages of CKD based 
on the level of kidney function, which are as follows [204]: 
•	 Stage 1: Normal or increased GFR (≥90 ml/min/1.73 m2)
•	 Stage 2: Mild reduction in GFR (60–89 ml/min/1.73 m2)
•	 Stage 3: Moderate reduction in GFR (30–59 ml/min/1.73 m2)
•	 Stage 4: Severe reduction in GFR (15–29 ml/min/1.73 m2)
•	 Stage 5: Kidney failure (GFR <15 ml/min/1.73 m2)
Stage 5 CKD is also called established CKD and is synonymous 
with the now outdated terms ESRD or chronic renal function. 
Severe CKD requires one of the forms of renal replacement ther-
apy, which may be in the form of dialysis but ideally constitutes 
a kidney transplant. 
The global increase in the number of patients with CKD and 
ESRD is a public health challenge in both developed and devel-
oping countries [14]. Approximately 8 million Americans have an 
estimated GFR less than 60 ml/min/1.73 m2 and 11 million have an 
estimated GFR greater than 60 ml/min/1.73 m2 but have persistent 
micro-albuminuria [15]. In the UK, the annual incidence of ESRD 
is around 100 per 1 million of the population (0.01%), which is 
expected to continue to rise by 5–6% annually (0.11% in 10 years). 
This incidence rate is approximately 336 and 135 per million in the 
USA and Europe, respectively [15,16]. The increase in prevalence of 
acute renal failure is a direct consequence of the increase in preva-
lence of diabetes and hypertension [17]. Patients with ESRD often 
require an average of more than seven medications to manage the 
underlying condition as well as the comorbid states [18]. Excessive 
use of drugs and incorrect dosage may lead to an increased risk of 
nephrotoxicity, which in turn leads to an escalation in the cost of 
patient care [19]. Thus, appropriate dosing of drugs in renal impair-
ment is an important consideration to avoid an increased incidence 
of adverse effects and to ensure optimal outcome for the patients. 
Dose adjustment of drugs excreted by the kidney is made according 
to the GFR.
Measurement of the rate of excretion of filtration markers such 
as inulin, iohexol and iothalamate are considered to be the gold 
standards for estimation of GFR. However, these studies are labor-
intensive and consequently, estimates of GFR are more commonly 
obtained from measurements of CL
CR
 or predictive models and 
equations based on serum creatinine levels. The equation in Box 1, 
which is referred to as the Cockcroft–Gault equation [20], is one of 
the most validated equations used to estimate CL
CR
 and is appli-
cable to patients with stable renal function. In the equation, BSA 
is the body surface area of the patient in units of m2. Although 
it is recognized that GFR may be overestimated by 10–20% in 
patients with moderate CKD, the Cockcroft–Gault equation is 
considered to be adequate for many clini-
cal decisions, including dosage adjustments 
in patients with impaired renal function. 
Values ranging from 120 to 140 ml/min 
are considered to be normal for GFR in an 
adult male.
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Box 1. The Cockcroft–Gault equation.
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The relationship that is referred to as the Modification of Diet 
in Renal Disease (MDRD) study equation (Box 2) [21], has gained 
increasing acceptance over the past few years. Many clinical lab-
oratories in Australia and the UK routinely report GFR results 
derived using the MDRD equation along with serum creatinine 
concentrations. There are fundamental differences between the 
Cockcroft–Gault and the MDRD equations to estimate GFR. 
First, the former was originally validated against CL
CR
 as the gold 
standard, whereas the latter was developed against iothalamate-
measured GFR. As creatinine, but not iothalamate, is excreted 
by both filtration and secretion, CL
CR
 always exceeds iothalamate 
clearance. Thus, estimates of GFR based on the Cockcroft–Gault 
equation tend to be higher than those based on the MDRD equa-
tion. Second, in contrast to the Cockcroft–Gault equation, which 
provides estimates of GFR in ml/min, the MDRD equation was 
developed to predict GFR standardized for a typical-sized adult 
with BSA of 1.73 m2. Therefore, it is necessary to estimate BSA in 
order to compare GFR estimates by the two methods. After this 
adjustment is made, the two equations perform similarly when 
compared with gold standards for measuring GFR; however, some 
studies have shown the MDRD equation to be superior [21,22]. It 
has been shown in various studies that MDRD GFR in general 
underestimates true GFR [23–25], especially in patients with normal 
GFR, whereas Cockcroft–Gault GFR overestimates true GFR, 
especially in patients with impaired kidney function [23]. 
Chronic kidney disease interferes with the elimination of many 
drugs as a result of the reduction in GFR and tubular secretion. The 
lack of dose adjustments in patients with renal insufficiency is an 
often overlooked, yet preventable, cause of drug dosing error [26]. 
Despite dose adjustment based on estimates of GFR, patients with 
CKD still present a large number of adverse events. Over the past 
decade, there has been emerging evidence to demonstrate that CKD 
also affects the nonrenal disposition of drugs that are extensively 
metabolized by the liver. Therefore, it is important to assess how 
CKD affects drug absorption and distribution, and changes in 
intestinal, hepatic and renal metabolism. The clinical relevance to 
pharmacokinetic changes observed in patients with CKD should be 
assessed on a case-by-case basis. CKD-induced changes in pharma-
cokinetics are not easily assessed or understood by most healthcare 
practitioners because these parameters are both drug- and patient-
specific. A review by Talbert [18], and more recently by Gabardi and 
Abramson [1], discusses the impact of CKD on drug disposition 
through changes in several pharmacokinetic parameters relating 
to the ADME processes.
IVIVE approaches: impact of CKD on  
physiological variables 
In this section, various IVIVE models for predicting absorption, 
distribution and clearance (CL) will be described. The key aspect of 
the IVIVE approach is the separation of information on the system 
(i.e., human body) from that of the drug (e.g., physicochemical 
characteristics determining permeability through membranes, 
partitioning to tissues, binding to plasma proteins, or affinities 
towards certain enzymes and transporter proteins) and the study 
design (e.g., dose, route and frequency of administration, concomi-
tant drugs and food). To our knowledge, this is the first time that 
the impact of CKD-induced changes on the system parameters 
of the IVIVE models, which ultimately lead to differences in the 
pharmacokinetics parameters, has been reported. 
The area under the concentration–time curve (AUC) is a measure 
of the exposure of an individual to a certain drug. The bioavailability 
of the drug (F) together with the CL and the dose of the drug (D) 
determine the overall exposure (AUC) according to this equation:
·AUC
CL
F D=
Total CL is defined as the volume of blood completely cleared 
of drug per unit time and encompasses clearance by the liver, the 
kidneys and biliary excretion (in the absence of reabsorption from 
the gut). Although exposure to the drug is determined only by 
the dose, CL and F, varying shapes of concentration–time profile 
can occur for a given exposure when the rate of entry (absorption 
rate, infusion rate, and so on) and rate of elimination are changed. 
Elimination rate is a function of CL and distribution characteristics. 
Bioavailability is defined as the proportion of an oral dose of 
a drug that reaches the systemic circulation in intact form and 
is dependent on a number of key factors that are described by 
the following equation:
F F F Fa G H# #=
where f
a
 is the fraction of dose that enters the gut wall; F
G
 is the 
fraction of drug that escapes first-pass metabolism in the gut wall 
and enters the portal vein; and F
H
 is the fraction of drug that enters 
the liver and escapes metabolism during first pass, which then 
enters the systemic circulation. 
The absorption potential of a drug can be estimated from physi-
ochemical properties using both empirical methods [27,28] and physi-
ological models such as the Compartmental Absorption and Transit 
(CAT) model [29]. The CAT model has been further developed into 
the Advanced Compartmental Absorption and Transit model [30] and 
the Advanced Dissolution, Absorption and Metabolism model [31]. 
In brief, these absorption models consist of physiologically based 
compartments corresponding to different segments of the GI tract. 
A series of differential equations are used to describe drug release, 
dissolution, degradation, metabolism and absorption within each 
segment and drug transit from one segment to the next. For each 
drug phase in the small intestine, for example, solid and dissolved 
drug, a segment is modeled as a well-stirred compartment in which 
different processes such as dissolution/precipitation, absorption/
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efflux/uptake and transit can occur simultaneously. Absorption is 
influenced by a number of physiological changes in the GI tract, 
some of which are observed in patients with CKD. Drug absorption 
may be altered as a result of changes in gastric emptying time and 
gastric pH, as well as the presence of gut edema [19]. Many patients 
with kidney impairment suffer from gastroparesis, which can delay 
gastric emptying [1] and cause prolongation of the maximum con-
centration (C
max
) without any apparent effect on the overall extent of 
absorption (TaBle 1). Conversely, the results of some studies in CKD 
patients show no delay in gastric emptying [32,33]. Conversion of 
salivary urea to ammonia by gastric urease may increase the gastric 
pH [34], which can alter the dissolution or ionization properties of 
certain drugs, resulting in changes to the bioavailability [8]. 
Distribution refers to the reversible transfer of a drug from one 
location to another within the body. The volume of distribution 
influences the elimination rate and C
max
 and, together with clear-
ance, determines the rate of decline in plasma drug concentrations 
(elimination rate) – the higher the volume, the longer the residence 
time in the body and vice versa. Since the proportion of the drug in 
different tissues changes with time (and the tissue–drug concentra-
tions are not necessarily moving in parallel), volume of distribution 
is not a fixed term and changes with time. The volume of distribu-
tion at steady state (V
ss
) is considered when the ratio of drug in vari-
ous tissues has reached equilibrium. Traditionally, after a drug has 
been administered intravenously, V
ss
 is calculated using this formula:
V
AUC
D MRTSS #=
where D and MRT are the dose and mean residence time, respec-
tively. However, this is an over-simplistic view of the processes 
involved [35]. Physiologically, an estimate of the volume of distri-
bution is based on an individual’s characteristics that go beyond 
simple links to body size [35] as described by the following equation:
:V V V E P V K ,SS p e t p t
1
# #+= +/
where V
p
, V
e
 and V
t
 are volumes of plasma, erythrocyte and tissue, 
respectively, and E:P and K
p,t
 are the relative drug concentrations in 
erythrocyte and tissue to plasma [36–42]. It is clear from this equa-
tion that there are system-related parameters that are characteristic 
of an individual (composition and volume of tissues) and drug-
related ones (binding affinity to red blood cells, plasma protein or 
certain components of tissues). It is well established that anemia 
develops in the course of CKD and its severity is related to the 
duration and extent of kidney failure (TaBle 1) [43]. Lower hemo-
globin may result from the reduced erythropoietin synthesis in 
the kidneys and/or the presence of inhibitors of erythropoiesis. 
In addition, decreased plasma protein binding of acidic drugs is 
often observed owing to reduced levels of albumin in the plasma 
(a direct consequence of hyperalbuminuria) (TaBle 1) [8,205], qualita-
tive changes in albumin binding sites and competition for binding 
sites by accumulating endogenous substances [44,45]. The unbound 
fraction of drug in plasma (fu) for an individual (fu
i
) based on the 
concentration of albumin in the plasma ([P
i
]) can be estimated 
using the following equation: 
[ ]
( ) [ ]
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P fu
fu P
1
1
1
i
i
#
#
=
+
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where [P] is the average concentration of albumin in the popula-
tion [46]. Changes in tissue protein binding are not relevant for 
most drugs, except in the case of digoxin, which leads to a 50% 
reduction in the V
ss
 in patients with stage 5 CKD [19]. CKD-
induced changes in body composition include increased total body 
water and adipose tissue and decreased muscle mass. Excessive 
fluid retention, manifesting as increased extracellular fluid, is 
expected to increase the V
ss
 of hydrophilic compounds [47].
Several models have been developed to quantify the effects 
of hepatic blood flow, fraction unbound in blood and hepatic 
intrinsic clearance on hepatic clearance [48]. Among these, the 
well-stirred model (represented by the two equations below) has 
been widely used mainly because of its 
mathematical simplicity and practicality, 
as shown below: 
·
· ·
CL
Q fu CLu
Q fu CLu
,
, ,
, ,
int
int
H B
H B B H
H B B H
=
+
F
Q fu CLu
Q
, ,
,
int
H
H B B H
H B
$
=
+
where CL
H,B
 is hepatic drug clearance 
based on whole-blood drug concentra-
tion, Q
H,B
 is hepatic blood flow and fu
B
 
is the free fraction of drug in blood. The 
well-stirred model assumes that drug dis-
tribution into the liver is perfusion limited 
with no diffusion delay and that no active 
transport systems are involved, and that the 
drug is distributed instantly and homog-
enously throughout liver water and that the 
unbound concentrations in plasma and liver 
water are identical. Rane et al. successfully 
Table 1. Key physiological and biochemical parameter changes 
associated with differing degrees of renal impairment.
Parameter Control GFR (ml/min/1.73 m2)
30–59 <30
CYP1A2 (pmol/mg) 52 [58] 33 [63,129–131] 24 [129–131]
CYP2C8 (pmol/mg) 24 [58] 20 [64] 13 [64]
CYP2C9 (pmol/mg) 73 [58] 63 [65] 29 [65]
CYP2C19 (pmol/mg) 14 [58] 5.5 [66] 2.3 [66]
CYP2D6 (pmol/mg) 8.0 [58] 4.6 [67,132,133] 2.1 [132,133]
CYP3A4 (pmol/mg) 137 [58] 73 [68,134,135] 62 [68,135]
Albumin (g.l-1) M
                       F
44.9 [205]
41.8 [205]
41.6 [136,137,205]
38.8 [136,137,205]
37.6 [136,137,205]
35.0 [136,137,205]
Hematocrit (%) M
                         F
43.0 [43]
38.0 [43]
39.7 [43]
33.2 [43]
36.5 [43]
31.3 [43]
Gastric emptying time (h) 0.40 [35] 0.55 [19] 0.65 [19]
F: Female; GFR: Glomerular filtration rate; M: Male.
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predicted in vivo hepatic metabolic clear-
ance in rats based on in vitro data obtained 
from rat liver microsomes, taking into con-
sideration the hepatic blood flow rate and 
the unbound fraction in blood [49]. Since 
then, significant progress has been made 
on predicting human hepatic metabolic 
clearance from a variety of in vitro systems, 
including human liver microsomes, recombinant enzymes and 
hepatocytes [50–55]. The unbound total hepatic intrinsic clearance 
(CLu
int,H
) can be extrapolated from in vitro clearance determined 
in a variety of in vitro systems using scaling factors as described 
in Barter et al. [56] and according to the approach described by 
Rostami-Hodjegan and Tucker [57]. The two equations shown in 
Box 3 represent the scaling approaches for recombinantly expressed 
enzymes and human liver microsomes. In the equations, there are 
i metabolic pathways for each of j enzymes; ‘rh’ indicates recom-
binantly expressed enzyme; Enz
i
abundance is the abundance of 
the ith CYP enzyme [58]; V
max
 is the maximum rate of metabolism 
by an individual enzyme; K
m
 is the Michaelis constant; MPPGL 
is the amount of microsomal protein per gram of liver; and ISEF 
is a scaling factor that compensates for any difference in the activ-
ity per unit of enzyme between recombinant systems and hepatic 
enzymes [59].
Drug metabolism & transporters
Drug metabolism is classified according to phase I or phase II 
processes. The cytochrome P450 (CYP450) family is the 
major phase I metabolic enzyme system in the liver. Pichette 
and Leblond have provided a detailed description of metabolic 
changes observed in renal failure and indicated that CKD was 
associated with a decrease in the expression of specific liver P450 
isoforms secondary to reduced mRNA levels [3]. However, most 
of these data come from in vitro and in vivo animal studies. The 
main hypothesis to explain the decrease in liver CYP activity 
in CKD appears to be the accumulation of uremic toxins (e.g., 
urea, indoxyl sulfate and cytokines), which can modulate CYP 
activity. There are a number of reports that have provided data in 
support of this hypothesis: indoxyl sulfate inhibited the metabo-
lism of ethoxyresorufin and testosterone in both human liver 
microsomes and hepatocytes [60]; parathyroid hormone down-
regulated hepatic P450 in rat and in cultured hepatocytes [61]; 
and incubations of microsomes from healthy human livers with 
serum of CKD patients led to decreases in CYP3A4 (80%), 
CYP2C9 (40%) and UDP-glucuronyl transferase activities [62]. 
Acute changes in the clearance of P450 substrates in experi mental 
models and in ESRD patients, associated with an improvement 
in the uremia (i.e., predialysis vs postdialysis), also support the 
concept that uremic toxins can directly inhibit drug metabo-
lism and transport in humans. Although there are no human 
liver data for patients with CKD demonstrating decreased CYP 
activity, there are many studies [3,4] that have shown that loss 
of renal function can result in decreased hepatic clearance of 
drugs metabolized by CYP1A2 [63], CYP2C8 [64], CYP2C9 [65], 
CYP2C19 [66], CYP2D6 [67] and CYP3A4 [68]. Extrapolation 
of these hepatic clearances back to values of metabolic intrinsic 
clearance (after correcting for differences in protein binding and 
blood to plasma partitioning) can provide estimates of enzyme 
abundance in patients with CKD (TaBle 1). 
More recently, the contribution of the gut to first-pass metabo-
lism has been increasingly recognized. The intestinal tissue is 
also endowed with phase I and II enzymes, although at lower 
levels than those for the liver [69]. Several CYP enzymes have 
been detected in the human small intestine, including CYP1A2, 
CYP2D6, CYP2E1, CYP2C8, CYP2C9, CYP2C19, CYP3A4 
and CYP3A5 [70]. Among them, CYP3A4 is the most prominent 
enzyme present in the human intestine [66,71]. Although the total 
content of CYP3A in the entire human small intestine is only 1% 
of that in the liver [67,72], intestinal extraction of CYP3A substrates 
is often similar to or even exceeds hepatic extraction [73].
An operational model to predict first-pass metabolism in the 
gut is available. The ‘Q
Gut
’ model (see the following equation) 
retains the form of the ‘well-stirred’ model but the flow term 
(Q
Gut
) is a hybrid of both permeability through the enterocyte 
membrane and villous blood flow [74,75].
·F Q fu CLu
Q
,int
G
Gut G G
Gut
=
+
where F
G
 is intestinal availability, fu
G
 is the fraction of drug 
unbound in the enterocyte and its value is close to 1 in most 
cases [71] and CLu
int,G
 is the unbound total gut intrinsic clearance. 
The parameter Q
Gut
 can be expanded:
·
Q
Q CL
Q CL
Gut
villi perm
villi perm
=
+
where CL
perm
 is a clearance term defining permeability through 
the enterocyte and Q
villi
 is villous blood flow. Permeability clear-
ance (CL
perm
) is the product of effective intestinal permeability 
(P
eff
) and intestinal cylindrical surface area [71]:
CL P Aperm eff #=
where A is intestinal cylindrical surface area and is variable among 
individuals. P
eff
 is related to drug permeability but can be affected by 
the abundances of intestinal transporters and pH in the gut lumen. 
CLu
int,G
 can be extrapolated from in vitro clearance determined in a 
variety of in vitro systems, including recombinantly expressed systems 
and human intestinal microsomes (Box 4). In these equations, there are 
i metabolic pathways for each of j enzymes; MPPGI is the amount 
of microsomal protein per gram of intestine, and ISEF is a scaling 
factor that compensates for any difference in the activity per unit 
of enzyme between recombinant systems and intestinal enzymes.
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Box 3. Scaling approach for estimation of hepatic metabolic 
intrinsic clearance.
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Although there are no in vivo or in vitro data derived from 
human tissues to support this, animal models of CKD have 
demonstrated reduced activity of intestinal CYP3A4 activity [76] 
and P-glycoprotein [77]. Reductions in intestinal metabolism and 
P-glycoprotein-mediated drug transport owing to CKD may cause 
an increase in the oral bioavailability of some drugs [9]. However, 
the results of a recent study by Sun et al. suggest that when using 
erythromycin as a model substrate, hepatic CL, but not gut bio-
availability, is affected in patients with ESRD [78]. This appears 
to be the first study in humans to differentiate between the effects 
of uremia on hepatic versus intestinal clearance.
In addition to reduced metabolic enzyme activity being respon-
sible for the reduced nonrenal clearance of drugs in a number of 
cases, other mechanisms such as alterations in transporter systems 
or transporter activity may be involved. Since transporters play 
an important role in drug disposition and elimination, more and 
more studies have begun to focus on their change in renal impair-
ment. These have been discussed extensively in a review by Sun 
et al. [78]. In the animal model of CKD, increasing evidence favors 
the hypothesis that kidney impairment modulates the number of 
uptake and efflux transporters in liver, kidney and intestine [78]. 
There is evidence based on animal studies that uremia has an inhib-
itory effect on the transport of organic anions into the liver [79,80]. 
Although there are IVIVE approaches available for incorporation 
of transporters [81,82], there are no relative abundance data or rela-
tive activity factors available for human liver that are necessary to 
correct for differences in uptake between healthy volunteers and 
subjects with renal impairment. 
Renal excretion
All drugs are ultimately removed from the body, either as metabo-
lites or in their unchanged form. The primary route of excretion is 
through the kidneys and urine, although excretion may also occur 
via the biliary route and be considered as a true elimination when 
there is no reabsorption occurring in the intestine. Compromised 
renal function may affect the pharmacokinetics of a drug if uri-
nary excretion is a substantial contributor to overall elimination. 
Drug characteristics that determine the extent of renal elimina-
tion include physical chemistry (lipophilicity and ionization) [83], 
plasma protein and erythrocyte binding [84] and affinity to certain 
transporter proteins in the kidney [85–87]. These mainly affect the 
fractional tubular reabsorption (F
Re-abs
), GFR or active secretion 
(CLu
Sec
) of the drug, which are summarized in equation in Box 
5 after Levy [84] and Janků [88].Chronic kidney disease-induced 
changes in the GFR, protein binding, blood to plasma partitioning 
and the renal blood flow (Q
R
) will obviously have a direct impact 
of the renal clearance of a drug (CL
R
). 
Although a comprehensive review of the literature was performed 
for all of the system parameters already described, including blood 
flows, only data relating to key changes are presented in TaBle 1; 
these include CYP abundance, protein binding, hematocrit and 
gastric emptying in subjects with varying degrees of renal impair-
ment (GFR <30 ml/min/1.73 m2 and 30–59 ml/min/1.73 m2). 
These system parameters used in conjunction with the ADME 
models described in this section can be used to assess the impact 
of CKD on the exposure (AUC and C
max
) of a drug. 
Application of IVIVE to predict pharmacokinetics in 
patients with renal impairment
In this section we present some examples of application of the 
IVIVE approach in subjects with renal impairment. The drugs 
that have been chosen have complex kinetics (undergo auto-inhi-
bition, have metabolites that are potent inhibitors and are taken up 
into the liver by transporters), undergo extensive metabolism in the 
liver and have negligible renal clearance. For each example, prior 
in vitro and in vivo information on the metabolism and kinetics 
of the drug were incorporated into the Simcyp Population-based 
Simulator [206] to predict the exposure of the drug in virtual sub-
jects with renal impairment and compared against in vivo data. 
The system parameters in TaBle 1 were used to generate a population 
of virtual individuals with varying degrees of renal impairment 
using a correlated Monte Carlo approach [31]. Residual variability 
was not incorporated into the simulations. 
The Simcyp Simulator adds intrinsic variability (i.e., coefficient 
of variation for parameters with uni- or multimodal frequency 
distributions depending on availability of information on the 
involvement of enzymes or transporters on kinetics and knowl-
edge of phenotype or genotype frequency for such polymorphic 
enzymes or transporters) to each parameter of the algorithms based 
on known information in the literature, and utilizes a correlated 
Monte Carlo approach to generate populations of different vir-
tual individuals with their own unique, but realistic, characteris-
tics. Early attempts to use Monte Carlo methods and to simulate 
pharmacokinetic behavior in ‘virtual populations’ date back to 
the mid-1980s. Jackson et al. assessed the robustness of different 
experimental in vivo indices to detect and display genetic poly-
morphisms in human drug-metabolizing activity [89,90]. These 
simulations were later expanded to demonstrate the effect of vari-
ability in ADME parameters on the power of single time point 
estimates for the assessment of metabolic activity [91]. Coupled with 
Monte Carlo methods, PBPK modeling has been used to assess 
the quantitative impact of physiological and environmental factors 
on human variability in toxicokinetics and pharmacokinetics in 
other publications [92–94]. 
Paroxetine
Paroxetine is a selective serotonin 
reuptake inhibitor antidepressant 
that is used to treat major depression 
and obsessive–compulsive, panic, 
social anxiety and generalized anxi-
ety disorders in adult outpatients. It 
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Box 4. Scaling approach for estimation of intestinal metabolic 
intrinsic clearance.
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is extensively metabolized in humans 
and exhibits nonlinear kinetics during 
single and multiple dosing [95,96]. After 
administration of a single dose of par-
oxetine, there is a sevenfold difference 
in the median total clearance of poor metabolizers (PMs) and 
extensive metabolizers (EMs) of CYP2D6, which is then reduced 
to twofold at steady state. The nonlinear kinetics of paroxetine 
are much more prominent in EMs than PMs, mainly owing to 
time-dependent inhibition of the CYP2D6-mediated metabo-
lism [97]. Jornil et al. used prior in vitro and in vivo information 
on the metabolism and kinetics of paroxetine to predict the expo-
sure in EM and PM individuals during single and multiple dos-
ing regimens [98]. The simulated data were reasonably consistent 
with in vivo data [97]. Hence, this model was used to predict the 
change in exposure of paroxetine in patients with differing degrees 
of renal impairment (GFR <30 ml/min/1.73 m2 and 30–59 ml/
min/1.73 m2) relative to healthy volunteers based on the study 
design described by Doyle et al. [99]. The renal function of the 
subjects recruited into the study was based on CL
CR
 estimated from 
serum creatinine levels. After a single oral dose of 30 mg parox-
etine, predicted fold increases in C
max
 and AUC
(0-∞)
 were 1.5- and 
1.7-fold, respectively, and 2.1- and 3.2-fold, respectively, for sub-
jects with GFR values between 30–59 and <30 ml/min/1.73 m2, 
respectively, relative to HV; corresponding in vivo increases were 
1.8- and 1.8- and 2.3- and 3.6-fold, respectively (Figure 1). After 
14 days of 30 mg paroxetine daily, predicted fold increases in C
max
 
and AUC on the last day of dosing relative 
to those in healthy volunteers were lower, as 
given by values of 1.3- and 1.3-fold, respec-
tively, and 1.5- and 1.6-fold, respectively, 
for the two groups. Although observed data 
were not available for the latter, it is impor-
tant to understand how the time-dependent 
inhibition of CYP2D6 propagates through 
multiple dosing regimens in patients with 
renal impairment. 
Diltiazem
The calcium channel antagonist diltiazem 
is used in the treatment of hyperten-
sion, angina pectoris and some types of 
arrhythmia, and is often prescribed in 
patients with renal impairment. The phar-
macokinetics of diltiazem in nine patients 
with severe renal impairment (GFR values 
based on inulin clearance ranging from 
1.8 to 52 ml/min/1.73 m2) receiving a sin-
gle 120 mg dose have been reported [100]. 
A direct comparison of the pharmacoki-
netics of diltiazem against those cited pre-
viously for healthy volunteers [101] led the 
investigators to conclude that diltiazem 
exposure was similar in both groups dur-
ing the administration of a single dose. 
However, there was considerable variability in peak plasma 
concentrations of diltiazem across the nine patients with renal 
impairment; values ranged from 31.9 to 406.4 ng/ml. 
This is probably due to the fact that diltiazem undergoes exten-
sive metabolism through multiple pathways, including deacetyla-
tion by esterases and CYP-mediated N- and O-demethylation. 
N-demethylation to desmethyldiltiazem (MA) appears to be 
the major pathway of elimination in humans and is mediated 
primarily by CYP3A, with minor contributions from CYP2C8 
and CYP2C9 [102,103]. MA is further N-demethylated, mainly by 
CYP3A, to N,N-didesmethyl diltiazem (MD) [104]. Diltiazem 
causes clinically significant drug–drug interactions with com-
pounds that are metabolized by CYP3A, including midazolam, 
triazolam, quinidine and simvastatin [105–107]. Thus, inhibition 
of CYP3A has been attributed to the parent compound and 
its metabolites, consistent with the accumulation of MA and 
desacetyl–diltiazem after 2 weeks of administration [108,109]. 
Subsequently, it was shown that both diltiazem and MA, but not 
MD, cause time-dependent inhibition through metabolite inter-
mediate complex formation, with MA having a fourfold greater 
inactivation potency than diltiazem [95]. We have previously pub-
lished on the development and validation of a mechanistic PBPK 
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Figure 2. Simulated plasma concentration–time profiles of diltiazem after an oral 
dose of 120 mg in subjects with severe renal impairment (glomerular filtration 
rate <30 ml/min/1.73 m2). The gray lines represent individual trials (10 × 9) and the solid 
black line is the mean of the population (n = 90). Mean observed data (Pozet et al. [100]) 
are overlaid (open circles). Inset: Dashed and solid lines represent simulated plasma 
concentrations in healthy volunteers and subjects with renal impairment, respectively.
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model that considers both competitive and time-dependent inhi-
bition in both gut and liver by both diltiazem and MA, as well 
as the complex interplay between the two moieties with respect 
to mutual inhibition of parent compound and its metabolite for 
both single and multiple dosage regimens [110]. 
This model was used in conjunction with the system param-
eters for the population with GFR <30 ml/min/1.73 m2 (TaBle 1) 
to replicate the study reported by Pozet et al. [100]. Simulated and 
observed mean plasma concentration–time profiles of a single 120-
mg dose of diltiazem administered to nine patients (five female) 
aged 22–69 years with severe renal impairment were compared 
for ten virtual trials (Figure 2). As observed for the in vivo study, 
there was considerable variability in peak plasma concentrations 
of diltiazem across the simulated patients with renal impairment; 
values ranged from 82.4 to 385 ng/ml. In the case of the observed 
data, this may be an artefact due to the limited number of blood 
samples that were taken (seven over a period of 12 h). Simulated 
profiles of diltiazem for both healthy volunteers and patients with 
renal impairment are shown in the inset of Figure 2. Despite the 45% 
reduction in CYP3A in patients with CKD, it is not surprising that 
the predicted exposures are similar because there is a 26% increase 
in the fu
p 
and the contribution of CYP3A metabolism to the overall 
clearance of diltiazem is less than 50%. During multiple dosing 
of diltiazem 120 mg three-times daily for 
14 days (data not shown), the accumulation 
of diltiazem is similar for the two groups. 
Repaglinide
Repaglinide is a short-acting meglitinide 
analogue antidiabetic drug used in the 
treatment of Type 2 diabetes mellitus [111]. 
It lowers blood glucose concentrations by 
enhancing glucose stimulated insulin release 
in pancreatic b-cells. Repaglinide is rapidly 
absorbed following oral administration and 
undergoes first-pass metabolism, resulting 
in a 60% bioavailability. CYP3A4 and 
CYP2C8 are the main enzymes responsible 
for the oxidative metabolism of the com-
pound [112,113]. The AUC of repaglinide is 
increased markedly in homozygous carri-
ers of the SLC01B1 521T>C (Val174Ala) 
single-nucleotide polymorphism, suggest-
ing that it is a substrate of the SLCO1B1-
encoded hepatic uptake transporter organic 
anion transporting polypeptide 1B1 
(OATP1B1) [114]. Prior in vitro and in vivo 
information on the metabolism and kinetics 
of repaglinide (including OATP1B1 uptake) 
were used in the Simcyp Population-based 
Simulator to simulate the plasma concen-
tration–time profiles of repaglinide and to 
predict the impact of renal impairment on 
the pharmacokinetics (C
max
 and AUC
(0-∞)
). 
The trial design used for simulation of 
the plasma drug concentration–time profiles following multiple 
doses of 2 mg repaglinide was based on the study of Marbury 
et al. [115] (Figures 3 & 4). Six healthy subjects (18–42 years of age; 
one female) and six patients (40–64 years of age; two female) with 
severe renal impairment (GFR <30 ml/min/m2) received a single 
dose of 2 mg repaglinide. On days 2–6, 2 mg repaglinide treat-
ment was given preprandially three-times a day, followed by a final 
single dose on day 7. The renal function of the subjects recruited 
into the study was assessed by two consecutive measurements of 
CL
CR
. After the last of multiple doses (2 mg) in healthy subjects 
and renal patients, predicted mean AUC
(0-∞)
 and C
max
 values ranged 
from 24.2 to 44.0 ng/ml.h (median 31.7) and 16.5 to 25.8 ng/ml 
(median 20.7), respectively, and from 35.6 to 77.3 ng/ml.h (median 
58.5) and 23.2 to 38.5 ng/ml (median 31.2), respectively (TaBle 2). 
Corresponding observed mean values were 22.2 ng/ml.h and 
16.4 ng/ml and 73.7 ng/ml.h and 29.9 ng/ml, respectively [115]. 
The predicted increases in AUC
(0-∞)
 and C
max
 in subjects with renal 
impairment relative to healthy volunteers were 1.3- and 1.5-fold, 
which were lower than the observed values (1.8- and 3.3-fold, 
respectively). Although it is known that uptake transporters have 
reduced activity in animal models of CKD [78], there are no quan-
titative data from human cell systems to use for extrapolation to 
in vivo. It is likely that if a reduction in OATP1B1-mediated uptake 
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Figure 1. Predicted and observed fold-increases in exposure (Cmax and AUC) after 
a single 30 mg dose of paroxetine in subjects with differing degrees of renal 
impairment (glomerular filtration rate <30 ml/min/1.73 m2 and 30–59 ml/min/
1.73 m2) relative to healthy volunteers based on the study design described by 
Doyle et al. [99].
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Figure 3. Simulated and observed plasma concentration–time profiles of repaglinide during a dosing schedule of a single 
dose of 2 mg repaglinide on day 1 followed by 2 mg repaglinide three-times daily on days 2–6 for healthy subjects (A) and 
for patients with renal impairment (B). The dashed lines represent individual trials (10 × 6) and the solid black lines are the mean of 
the population (n = 60). The circles are mean observed values from Marbury et al. [115]. 
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Figure 4. Simulated and observed plasma concentration–time profiles of repaglinide on the last day during a dosing 
schedule of a single dose of 2 mg repaglinide on day 1 followed by 2 mg repaglinide three-times daily on days 2–6 to 
healthy subjects (A) and patients with renal impairment (B). The gray lines represent individual trials (10 × 6) and the solid black 
lines are the mean of the population (n = 60). The circles are mean observed values from Marbury et al. [115].
(which results in reduced metabolism and increased exposure) of 
repaglinide was incorporated into the model, the observed data in 
patients with renal impairment would be recovered.
Expert commentary
The pharmaceutical industry and drug regulatory bodies are 
increasingly embracing the application of modeling and simula-
tion to predict human pharmacokinetics from in vitro data and 
animal models to produce innovative products faster and more 
safely. Indeed, over the past decade there have been an increasing 
number of publications on the application of IVIVE approaches 
in the drug development process [116–127].
Modeling and simulation of ADME processes that define the 
plasma concentration–time course of a drug also provide a tool 
for prediction of interindividual variability in dose–concentration 
relationships, which is of particular importance to clinicians, as 
well as scientists working in drug development. Regulatory bodies, 
notably the FDA in the USA, have already emphasized the need for 
quantitative description of pharmacokinetics through its Critical 
Path Initiative, in an attempt to underpin the understanding of 
efficacy, safety and optimal study design with a view to informing 
regulatory decisions [128]. The FDA has proposed a decision tree 
recommending that drugs eliminated predominantly by nonrenal 
routes should be investigated using a reduced pharmacokinetic 
study in subjects with ESRD in the first instance [9], followed by 
a full study if the results demonstrate an important alteration in 
pharmacokinetics. Therefore, it is envisaged that PBPK modeling 
will be utilized more frequently to provide an indication of the 
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change in drug exposure in special populations that cannot be tar-
geted for ethical reasons, including those with renal impairment, 
and facilitate the design of more efficient clinical trials. Based on 
the examples presented in this article, it appears that it may be 
possible to use IVIVE approaches to predict the pharmacokinetics 
of drugs eliminated predominantly by nonrenal routes in patients 
with renal impairment using a PBPK approach. However, more 
extensive validation of the existing model and additional research 
into the physiological changes induced by CKD are required to 
refine the model. 
Five-year view
While the use of IVIVE in conjunction with PBPK models 
appears to have been accepted by the pharmaceutical industry 
and regulatory bodies, it is likely that application of this approach 
to special populations, including those 
with renal impairment, will take longer 
to adopt owing to the high risk of adverse 
events associated with these individuals. 
Based on the examples provided in this 
article, it appears that it may be possible to 
extrapolate this approach to patients with 
renal impairment. Further research into the 
effects of CKD on the system parameters 
required for IVIVE will hopefully aid in 
the development of more robust models.
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Key issues
• Renal impairment not only affects elimination of the drug in the kidney, but also the nonrenal route of drugs that are extensively 
metabolized in the liver. 
• The US FDA guidance to assess the impact of renal impairment on the pharmacokinetics of a drug under development has recently been 
updated to include evaluation of drugs with nonrenal elimination routes. 
• Prior simulation of the potential exposure of individuals with renal impairment may help in the selection of a safe and effective 
dosage regimen. 
• In addition to reduced metabolic enzyme activity being responsible for the reduced nonrenal clearance of drugs in a number of cases, 
other mechanisms such as alterations in transporter systems or transporter activity may be involved.
• These factors can be accommodated using a ‘systems biology’ approach and full physiologically based pharmacokinetic models.
• Although results generated using the physiologically based pharmacokinetic models appear to be reasonably consistent with observed 
data for patients with renal impairment, more extensive validation is required.
• Quantitative data relating to in vitro–in vivo extrapolation of transporters, including relative activity factors, are required to incorporate 
the effects of renal impairment on transporter-mediated uptake. 
Table 2. Mean predicted Cmax and AUC values of repaglinide on the 
last day of 7 days of dosing with 2 mg repaglinide (2 mg for 1 day 
followed by 2 mg three-times a day for 6 days).
Predicted or 
observed
Healthy subjects
(n = 6)
Patients with renal 
impairment (n = 6)
AUC
(ng/ml.h)
Cmax
(ng/ml)
AUC
(ng/ml.h)
Cmax
(ng/ml)
Predicted† 24.2–44.0 
(31.7)
16.5–25.8 
(20.7)
35.6–77.3 
(58.5)
23.2–38.5 
(31.2)
Observed 22.2 16.4 73.7 29.9
†A range of mean values for the ten simulated trials and the corresponding median in brackets are shown.
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